"Antigens, CD19" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Differentiation antigens expressed on B-lymphocytes and B-cell precursors. They are involved in regulation of B-cell proliferation.
| Descriptor ID |
D018941
|
| MeSH Number(s) |
D23.050.301.264.035.119 D23.050.301.264.051.119 D23.050.301.500.600.200 D23.050.705.552.600.200 D23.101.100.110.119 D23.101.100.150.119
|
| Concept/Terms |
Antigens, CD19- Antigens, CD19
- CD19 Antigens
- B Cell Antigen CD19
- CD19 Antigen
- Antigen, CD19
|
Below are MeSH descriptors whose meaning is more general than "Antigens, CD19".
- Chemicals and Drugs [D]
- Biological Factors [D23]
- Antigens [D23.050]
- Antigens, Surface [D23.050.301]
- Antigens, Differentiation [D23.050.301.264]
- Antigens, CD [D23.050.301.264.035]
- Antigens, CD19 [D23.050.301.264.035.119]
- Antigens, Differentiation, B-Lymphocyte [D23.050.301.264.051]
- Antigens, CD19 [D23.050.301.264.051.119]
- Histocompatibility Antigens [D23.050.301.500]
- Minor Histocompatibility Antigens [D23.050.301.500.600]
- Antigens, CD19 [D23.050.301.500.600.200]
- Isoantigens [D23.050.705]
- Histocompatibility Antigens [D23.050.705.552]
- Minor Histocompatibility Antigens [D23.050.705.552.600]
- Antigens, CD19 [D23.050.705.552.600.200]
- Biomarkers [D23.101]
- Antigens, Differentiation [D23.101.100]
- Antigens, CD [D23.101.100.110]
- Antigens, CD19 [D23.101.100.110.119]
- Antigens, Differentiation, B-Lymphocyte [D23.101.100.150]
- Antigens, CD19 [D23.101.100.150.119]
Below are MeSH descriptors whose meaning is more specific than "Antigens, CD19".
This graph shows the total number of publications written about "Antigens, CD19" by people in this website by year, and whether "Antigens, CD19" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 1998 | 1 | 0 | 1 |
| 2001 | 0 | 1 | 1 |
| 2002 | 1 | 0 | 1 |
| 2004 | 0 | 1 | 1 |
| 2006 | 1 | 3 | 4 |
| 2009 | 0 | 1 | 1 |
| 2010 | 2 | 4 | 6 |
| 2011 | 0 | 3 | 3 |
| 2012 | 0 | 1 | 1 |
| 2013 | 2 | 0 | 2 |
| 2014 | 3 | 4 | 7 |
| 2015 | 1 | 0 | 1 |
| 2016 | 1 | 4 | 5 |
| 2017 | 1 | 2 | 3 |
| 2018 | 3 | 1 | 4 |
| 2019 | 2 | 2 | 4 |
| 2020 | 2 | 1 | 3 |
| 2021 | 1 | 1 | 2 |
| 2022 | 0 | 11 | 11 |
| 2023 | 0 | 7 | 7 |
| 2024 | 1 | 3 | 4 |
| 2025 | 4 | 0 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antigens, CD19" by people in Profiles.
-
Infection after CD19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma: real-world analysis from CIBMTR. Blood Adv. 2025 Nov 11; 9(21):5460-5472.
-
A novel homozygous frameshift mutation likely causing nonsense-mediated mRNA decay in an Algerian kindred with CD19 complex deficiency. Front Immunol. 2025; 16:1634146.
-
Cytokine Release Syndrome and Neurotoxicity Following CD19 CAR-T in B-Cell Lymphoma. Transplant Cell Ther. 2025 Jul; 31(7):419-433.
-
Real-world comparison of lisocabtagene maraleucel and axicabtagene ciloleucel in large B-cell lymphoma: an inverse probability of treatment weighting analysis with 3-year follow-up. Haematologica. 2025 Sep 01; 110(9):2040-2054.
-
Lisocabtagene maraleucel for relapsed/refractory large B-cell lymphoma: a cell therapy consortium real-world analysis. Blood Adv. 2025 Mar 11; 9(5):1232-1241.
-
EASIX and m-EASIX predict CRS and ICANS in pediatric and AYA patients after CD19-CAR T-cell therapy. Blood Adv. 2025 Jan 28; 9(2):270-279.
-
Outcomes of CD19 CAR T in Transformed Indolent Lymphoma Compared to De Novo Aggressive Large B-Cell Lymphoma. Am J Hematol. 2025 Feb; 100(2):236-248.
-
Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia. N Engl J Med. 2024 Dec 12; 391(23):2219-2230.
-
Optimizing the post-CAR T monitoring period in recipients of axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel. Blood Adv. 2024 10 22; 8(20):5346-5354.
-
Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL. J Clin Oncol. 2025 Feb 10; 43(5):558-566.